Education
About Us
Working with TipRanks
Follow Us
Kymera Therapeutics, Inc. (KYMR)
:KYMR
KYMR Analyst Ratings
Strong Buy
17 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
KYMR Stock 12 Month Forecast
Average Price Target
$60.63
▲(39.60%Upside)
| Highest Price Target$70.00 | Average Price Target$60.63 | Lowest Price Target$50.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$50
Hold
15.13%
Upside
Reiterated
06/25/25
Kymera Therapeutics benefits from strong technical momentum and strategic corporate partnerships, which enhance its growth outlook despite current financial challenges. The company's substantial cash reserves and promising pipeline developments further support future potential, although the negative cash flow and earnings remain significant risks.
Brookline Capital Markets
$70→$65
Buy
49.67%
Upside
Reiterated
07/07/25
Morgan Stanley
$79→$70
Buy
61.18%
Upside
Initiated
07/03/25
BTIG
$55→$59
Buy
35.85%
Upside
Reiterated
07/01/25
Bank of America Securities
$51→$54
Buy
24.34%
Upside
Reiterated
06/27/25
Truist Financial
―
Buy
―
Reiterated
06/26/25
Wells Fargo
$57→$53
Buy
22.04%
Upside
Reiterated
06/26/25
H.C. Wainwright
$54→$60
Buy
38.15%
Upside
Reiterated
06/26/25
TD Cowen
―
Buy
―
Reiterated
06/26/25
Oppenheimer
$56→$53
Buy
22.04%
Upside
Reiterated
06/26/25
Leerink Partners
$60
Buy
38.15%
Upside
Reiterated
06/25/25
Jefferies
$66→$64
Buy
47.36%
Upside
Reiterated
06/25/25
B.Riley Financial
$38→$60
Buy
38.15%
Upside
Upgraded
06/03/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$50
Hold
15.13%
Upside
Reiterated
06/25/25
Kymera Therapeutics benefits from strong technical momentum and strategic corporate partnerships, which enhance its growth outlook despite current financial challenges. The company's substantial cash reserves and promising pipeline developments further support future potential, although the negative cash flow and earnings remain significant risks.
Brookline Capital Markets
$70→$65
Buy
49.67%
Upside
Reiterated
07/07/25
Morgan Stanley
$79→$70
Buy
61.18%
Upside
Initiated
07/03/25
BTIG
$55→$59
Buy
35.85%
Upside
Reiterated
07/01/25
Bank of America Securities
$51→$54
Buy
24.34%
Upside
Reiterated
06/27/25
Truist Financial
―
Buy
―
Reiterated
06/26/25
Wells Fargo
$57→$53
Buy
22.04%
Upside
Reiterated
06/26/25
H.C. Wainwright
$54→$60
Buy
38.15%
Upside
Reiterated
06/26/25
TD Cowen
―
Buy
―
Reiterated
06/26/25
Oppenheimer
$56→$53
Buy
22.04%
Upside
Reiterated
06/26/25
Leerink Partners
$60
Buy
38.15%
Upside
Reiterated
06/25/25
Jefferies
$66→$64
Buy
47.36%
Upside
Reiterated
06/25/25
B.Riley Financial
$38→$60
Buy
38.15%
Upside
Upgraded
06/03/25
Best Analysts Covering Kymera Therapeutics
1 Month
xxx
Success Rate
5/6 ratings generated profit
Average Return
+15.42%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 83.33% of your transactions generating a profit, with an average return of +15.42% per trade.
3 Months
xxx
Success Rate
8/12 ratings generated profit
Average Return
+32.91%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +32.91% per trade.
1 Year
Success Rate
9/12 ratings generated profit
Average Return
+44.39%
reiterated a buy rating 15 days ago
Copying Marc Frahm's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +44.39% per trade.
2 Years
xxx
Success Rate
11/13 ratings generated profit
Average Return
+45.12%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 84.62% of your transactions generating a profit, with an average return of +45.12% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
KYMR Analyst Recommendation Trends
Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
11
10
11
13
14
Buy
7
5
4
26
26
Hold
4
3
5
6
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
22
18
20
45
45
Each month's total comprises the sum of three months' worth of ratings.
KYMR Financial Forecast
KYMR Stock Forecast FAQ
What is KYMR’s average 12-month price target, according to analysts?
Based on analyst ratings, Kymera Therapeutics, Inc.’s 12-month average price target is 60.63.
What is KYMR’s upside potential, based on the analysts’ average price target?
Kymera Therapeutics, Inc. has 39.60% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is KYMR a Buy, Sell or Hold?
Kymera Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 17 buy ratings, 1 hold ratings and 0 sell ratings.
What is Kymera Therapeutics, Inc.’s price target?
The average price target for Kymera Therapeutics, Inc. is 60.63. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $70.00 ,the lowest forecast is $50.00. The average price target represents 39.60% Increase from the current price of $43.43.
The highest analyst price target is $70.00 ,the lowest forecast is $50.00. The average price target represents 39.60% Increase from the current price of $43.43.
What do analysts say about Kymera Therapeutics, Inc.?
Kymera Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.
How can I buy shares of KYMR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.